Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.
The versatile portfolio of Restylane HA treatments is designed to meet diverse patient needs across key areas of the face and décolletage, from soft, flexible formulations that smooth facial lines and ...
Early calls, unexpected plans and moments you can’t plan are part of everyday living: and modern beauty should keep up. With ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for ...
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics ...
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA ® lidocaine range of Restylane ...
Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane as an everyday beauty ally. Aligned with the growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results